These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 18655904

  • 1. Affinity and efficacy of selective agonists and antagonists for vasopressin and oxytocin receptors: an "easy guide" to receptor pharmacology.
    Chini B, Manning M, Guillon G.
    Prog Brain Res; 2008; 170():513-7. PubMed ID: 18655904
    [Abstract] [Full Text] [Related]

  • 2. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G.
    Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
    [Abstract] [Full Text] [Related]

  • 3. Pharmacologic characterization of the oxytocin receptor in human uterine smooth muscle cells.
    Tahara A, Tsukada J, Tomura Y, Wada Ki, Kusayama T, Ishii N, Yatsu T, Uchida W, Tanaka A.
    Br J Pharmacol; 2000 Jan; 129(1):131-9. PubMed ID: 10694212
    [Abstract] [Full Text] [Related]

  • 4. Agonist selectivity in the oxytocin/vasopressin receptor family: new insights and challenges.
    Chini B, Manning M.
    Biochem Soc Trans; 2007 Aug; 35(Pt 4):737-41. PubMed ID: 17635137
    [Abstract] [Full Text] [Related]

  • 5. Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist.
    Frantz MC, Rodrigo J, Boudier L, Durroux T, Mouillac B, Hibert M.
    J Med Chem; 2010 Feb 25; 53(4):1546-62. PubMed ID: 20104850
    [Abstract] [Full Text] [Related]

  • 6. Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor.
    Chan WY, Wo NC, Cheng LL, Manning M.
    J Pharmacol Exp Ther; 1996 May 25; 277(2):999-1003. PubMed ID: 8627583
    [Abstract] [Full Text] [Related]

  • 7. The discovery of novel vasopressin V1b receptor ligands for pharmacological, functional and structural investigations.
    Guillon G, Derick S, Pena A, Cheng LL, Stoev S, Seyer R, Morgat JL, Barberis C, Gal CS, Wagnon J, Manning M.
    J Neuroendocrinol; 2004 Apr 25; 16(4):356-61. PubMed ID: 15089974
    [Abstract] [Full Text] [Related]

  • 8. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
    Pena A, Murat B, Trueba M, Ventura MA, Wo NC, Szeto HH, Cheng LL, Stoev S, Guillon G, Manning M.
    J Med Chem; 2007 Feb 22; 50(4):835-47. PubMed ID: 17300166
    [Abstract] [Full Text] [Related]

  • 9. Non-peptide oxytocin agonists.
    Pitt GR, Batt AR, Haigh RM, Penson AM, Robson PA, Rooker DP, Tartar AL, Trim JE, Yea CM, Roe MB.
    Bioorg Med Chem Lett; 2004 Sep 06; 14(17):4585-9. PubMed ID: 15357997
    [Abstract] [Full Text] [Related]

  • 10. Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.
    Albizu L, Teppaz G, Seyer R, Bazin H, Ansanay H, Manning M, Mouillac B, Durroux T.
    J Med Chem; 2007 Oct 04; 50(20):4976-85. PubMed ID: 17850055
    [Abstract] [Full Text] [Related]

  • 11. Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin.
    Gimpl G, Postina R, Fahrenholz F, Reinheimer T.
    Eur J Pharmacol; 2005 Mar 07; 510(1-2):9-16. PubMed ID: 15740719
    [Abstract] [Full Text] [Related]

  • 12. Discovery and design of novel vasopressin hypotensive peptide agonists.
    Manning M, Stoev S, Cheng LL, Wo NC, Chan WY.
    J Recept Signal Transduct Res; 1999 Mar 07; 19(1-4):631-44. PubMed ID: 10071789
    [Abstract] [Full Text] [Related]

  • 13. Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.
    Terrillon S, Cheng LL, Stoev S, Mouillac B, Barberis C, Manning M, Durroux T.
    J Med Chem; 2002 Jun 06; 45(12):2579-88. PubMed ID: 12036367
    [Abstract] [Full Text] [Related]

  • 14. A Gly/Ala switch contributes to high affinity binding of benzoxazinone-based non-peptide oxytocin receptor antagonists.
    Hawtin SR, Ha SN, Pettibone DJ, Wheatley M.
    FEBS Lett; 2005 Jan 17; 579(2):349-56. PubMed ID: 15642343
    [Abstract] [Full Text] [Related]

  • 15. Discovery and optimization of highly ligand-efficient oxytocin receptor antagonists using structure-based drug design.
    Bellenie BR, Barton NP, Emmons AJ, Heer JP, Salvagno C.
    Bioorg Med Chem Lett; 2009 Feb 01; 19(3):990-4. PubMed ID: 19095447
    [Abstract] [Full Text] [Related]

  • 16. Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala.
    Huber D, Veinante P, Stoop R.
    Science; 2005 Apr 08; 308(5719):245-8. PubMed ID: 15821089
    [Abstract] [Full Text] [Related]

  • 17. Molecular docking-based study of vasopressin analogues modified at positions 2 and 3 with N-methylphenylalanine: influence on receptor-bound conformations and interactions with vasopressin and oxytocin receptors.
    Slusarz MJ, Sikorska E, Slusarz R, Ciarkowski J.
    J Med Chem; 2006 Apr 20; 49(8):2463-9. PubMed ID: 16610789
    [Abstract] [Full Text] [Related]

  • 18. Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system.
    Slusarz MJ, Slusarz R, Ciarkowski J.
    Biopolymers; 2006 Apr 05; 81(5):321-38. PubMed ID: 16333859
    [Abstract] [Full Text] [Related]

  • 19. 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics.
    Borthwick AD, Davies DE, Exall AM, Livermore DG, Sollis SL, Nerozzi F, Allen MJ, Perren M, Shabbir SS, Woollard PM, Wyatt PG.
    J Med Chem; 2005 Nov 03; 48(22):6956-69. PubMed ID: 16250654
    [Abstract] [Full Text] [Related]

  • 20. Comparative pharmacology of bovine, human and rat vasopressin receptor isoforms.
    Andrés M, Peña A, Derick S, Raufaste D, Trojnar J, Wisniewski K, Trueba M, Serradeil-Le Gal C, Guillon G.
    Eur J Pharmacol; 2004 Oct 06; 501(1-3):59-69. PubMed ID: 15464063
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.